Key Highlights
Liminatus Pharma stock jumps 31% following Nasdaq delisting notification, then retreats in pre-market hours.
Biotech company falls short of Nasdaq’s $50M market cap and $15M public float standards.
Appeal deadline set for May 27 to avoid trading halt beginning May 29.
Extreme price swings reflect investor uncertainty over compliance outcome.
Filing for hearing will temporarily halt delisting process, allowing compliance opportunity.
Shares of Liminatus Pharma, Inc. (LIMN) experienced dramatic upward movement following the announcement of a Nasdaq delisting notification. The biotechnology stock finished the trading session at $0.2460, representing a gain of 30.99%. However, pre-market activity showed a reversal, with shares tumbling to $0.1830, wiping out the majority of previous gains.
Liminatus Pharma, Inc. Class A Common Stock, LIMN
The company has fallen below Nasdaq’s minimum standard requiring a $50 million market valuation for listed securities. The firm also missed the exchange’s $15 million threshold for publicly traded shares value. Initially, Nasdaq provided a 180-day grace period for the company to achieve compliance.
Unless Liminatus files an appeal with the Nasdaq Hearings Panel before May 27, 2026, delisting proceedings will move forward. Should the firm fail to submit an appeal, trading would halt starting May 29, 2026. The company has announced its intention to pursue a hearing to prevent suspension.
Understanding Nasdaq’s Compliance Standards and Deadlines
Nasdaq Listing Standard 5450(b)(2)(A) establishes a floor of $50 million in market value for securities listed on the exchange. This regulation is designed to maintain appropriate market capitalization levels for ongoing listing eligibility. Liminatus was unable to satisfy this benchmark before the May 18, 2026 cutoff date.
Another requirement outlined in Rule 5450(b)(2)(C) establishes a minimum of $15 million for publicly available shares. This provision guarantees adequate trading volume and market liquidity for investor protection. The pharmaceutical company failed to achieve this standard during the designated 180-day compliance window.
Should the biotech firm’s appeal receive approval, both the suspension and delisting procedures will be temporarily halted. This reprieve would allow Liminatus to demonstrate its compliance strategy before the Nasdaq Panel. The panel’s decision will ultimately decide the stock’s listing fate.
Investor Response and Company History
Trading in LIMN shares has been marked by significant price fluctuations since the delisting announcement. The market responded dramatically to both the initial surge and subsequent pre-market decline. These volatile trading patterns illustrate investor concerns about regulatory compliance and corporate direction.
The pharmaceutical company initially revealed these compliance challenges through an 8-K filing submitted on November 25, 2025. Trading below the mandated market capitalization levels began on November 19, 2025. The exchange issued several warnings and compliance deadlines during this period.
This situation underscores Nasdaq’s rigorous application of its listing criteria. Firms unable to satisfy MVLS and MVPHS standards encounter swift regulatory action. The pending appeal will be decisive in whether Liminatus maintains its position on the Nasdaq Global Market.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
